John Souglakos
University of Crete · 272 works · 8,813 citations · h-index 46
Top works
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
- FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
- IGF-I and IGF-II in relation to colorectal cancer
- Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial
- Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
- BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
- Frontline Treatment of Advanced Gastric Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor (G-CSF)
- OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
- Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database
- Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
- Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.
- ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
- Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
- BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
- Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
- First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study
- Successful Conservative Treatment of Neutropenic Enterocolitis Complicating Taxane-Based Chemotherapy